Technology ID
E-573-2013-0

Novel Targets to Prevent Borrelia burgdorferi Infection and Lyme Disease

Linked ID
TAB-2666
Inventors
Robert Gilmore (CDC)
Lead Inventors
Robert Gilmore (CDC)
Development Status
  • Early-stage
  • In vitro data available
  • In vivo data available (animal)
Applications
Therapeutics
Therapeutic Areas
Infectious Disease
ICs
CDC
Commercial Applications
  • B. burgdorferi/Lyme disease vaccine development
  • B. burgdorferi diagnostics
  • Prevention of B. burgdorferi infection by passive immunity
  • Zoonotic/tick-borne disease surveillance
  • Public health vaccination programs against Lyme disease
B. burgdorferi-infected ticks can cause Lyme disease in mammalian hosts. This technology relates to the use of B. burgdorferi outer surface proteins (BBA64 and BBA66) as Lyme disease vaccine candidates. In vivo animal studies demonstrate these outer surface proteins inhibit tick-to-host B. burgdorferi transmission. Presently, there is no vaccine approved for Lyme disease.
Competitive Advantages
  • Currently no approved Lyme disease vaccines

Request More Info